Twitter LinkedIn YouTube iTune Podcast Google Podcasts Spotify

StageZero Life Sciences Ltd. TSX: SZLS

InvestorIntel Features on StageZero Life Sciences Ltd.

Early identification of colon cancer blood test places healthcare in patients hands

In the news release announced this morning about one of the first blood tests to aid in the early identification of […]

One test, ten cancers, unlimited possibilities – should be a big hit!

One test, ten cancers, unlimited possibilities. A new way to screen for many cancers all in one go should be […]

StageZero’s James Howard-Tripp on diagnosing cancer early

“We are all about finding diseases early. Our current focus is on cancer. If you can find it early your […]

Company Overview

TeamWebsite

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which was validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer. Further validation of Aristotle is currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.

News Releases

View All News

Twitter LinkedIn YouTube Amazon Alexa iTune Podcast Google Podcasts Spotify